Biohaven Revenue 2016-2023 | BHVN

Biohaven revenue from 2016 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Biohaven Annual Revenue
(Millions of US $)
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
Biohaven Quarterly Revenue
(Millions of US $)
2023-03-31
2022-12-31
2022-09-30
2022-06-30 $215
2022-03-31
2021-12-31
2021-09-30
2021-06-30 $93
2021-03-31 $44
2020-12-31
2020-09-30 $18
2020-06-30 $10
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.195B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $135.379B 8.27
GSK (GSK) United Kingdom $68.795B 9.60
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.284B 21.71
Ginkgo Bioworks Holdings (DNA) United States $3.295B 0.00
Arcus Biosciences (RCUS) United States $1.502B 0.00
Emergent Biosolutions (EBS) United States $0.430B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.181B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00